Kinali, HurmetKalaycioglu, Gokce DicleBoyacioglu, OzgeKorkusuz, PetekAydogan, NihalVargel, IbrahimBasic Sciences2024-09-102024-09-10202400141-81301879-000310.1016/j.ijbiomac.2024.1336612-s2.0-85198272954https://doi.org/10.1016/j.ijbiomac.2024.133661https://hdl.handle.net/20.500.14411/7302Boyacioglu, Ozge/0000-0001-5240-8209Chronic wounds are often caused by diabetes and present a challenging clinical problem due to vascular problems leading to ischemia. This inhibits proper wound healing by delaying inflammatory responses and angiogenesis. To address this problem, we have developed injectable particle-loaded hydrogels which sequentially release Granulocyte-macrophage- colony-stimulating-factor (GM-CSF) and Vascular endothelial growth factor (VEGF) encapsulated in polycaprolactone-lecithin-geleol mono-diglyceride hybrid particles. GM-CSF promotes inflammation, while VEGF facilitates angiogenesis. The hybrid particles (200 -1000 nm) designed within the scope of the study can encapsulate the model proteins Bovine Serum Albumin 65 +/- 5 % and Lysozyme 77 +/- 10 % and can release stably for 21 days. In vivo tests and histological findings revealed that in the hydrogels containing GM-CSF/VEGF-loaded hybrid particles, wound depth decreased, inflammation phase increased, and fibrotic scar tissue decreased, while mature granulation tissue was formed on day 10. These findings confirm that the hybrid particles first initiate the inflammation phase by delivering GM-CSF, followed by VEGF, increasing the number of vascularization and thus increasing the healing rate of wounds. We emphasize the importance of multi-component and sequential release in wound healing and propose a unifying therapeutic strategy to sequentially deliver ligands targeting wound healing stages, which is very important in the treatment of the diabetic wounds.eninfo:eu-repo/semantics/closedAccessVEGFGM-CSFDiabetic woundArticleQ1Q1276WOS:00127200020000138992546